Skip to Content

Project 2: Cell Specific Targeting of Ovarian Cancer Vasculature

Publications

Note: Bold indicates an investigator affiliated with the MD Anderson Ovarian Cancer SPORE or an Ovarian Cancer SPORE at another institution.

  1. Xu L, Xie K, Mukaida N, Matsushima K, Fidler IJ. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells. Cancer Res 1999; 59:5822-29. PMID: 10582705.
    Abstract
  2. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000; 16:445-54. PMID: 10675474.
    Abstract
  3. Xu L, Fidler IJ. Acidic pH-induced elevation in interleukin-8 expression by human ovarian carcinoma. Cancer Res 2000; 60:4610-6. PMID: 10969814.
    Abstract
  4. Huang S, Robinson JB, DeGuzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin-8. Cancer Res (Adv in Brief) 2000; 60:5334-9. PMID: 11034066.
    Abstract
  5. Xu L, Fidler IJ. Interleukin-8: an autocrine growth factor for human ovarian cancer. Oncology Res 2000; 12:97-106. PMID: 11132928.
    Abstract
  6. Herrera CA, Xu L, Bucana CD, Silva EG, Hess KR, Gershenson DM, Fidler IJ. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol 2002; 20:5-13. PMID: 11743636.
    Full Text (pdf)
  7. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and qualitative in vivo angiogenesis assay. Int J. Oncol 2002; 21:5-10. PMID: 12063542.
    Full Text (pdf)
  8. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002; 12:89-96. PMID: 12027580.
    Abstract
  9. Lu W, Dong Z, Donawho C, Fidler IJ. Specific immunotherapy against occult cancer metastasis. Int J Cancer 2002; 100:480-5. PMID: 12115534.
    Abstract
  10. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon-α combined with paclitaxel. Clin Cancer Res 2002; 8:2413-22. PMID: 12114447.
    Abstract
  11. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst 2002; 94:1134-42. PMID: 12165638.
    Abstract
  12. Baker CH, Kedar D, McCarty MF, Tsan R, Weber KL, Bucana CD, Fidler IJ. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002; 161:929-38. PMCID: PMC1867249.
    Abstract
  13. Fidler IJ. The organ microenvironment and cancer metastasis (Review). Differentiation 2002; 70:498-505. PMID: 12492492.
    Abstract
  14. Onn A, Fidler IJ. Metastatic potential of human neoplasms. In Vivo 2002; 16:423-9. PMID: 12494885.
    Abstract
  15. Fidler IJ, Yoneda J, Herrera C, Wood J, Xu L. Specific keynote: molecular determinants of angiogenesis in ovarian cancer. Gynecol Oncol 2003; 88(1 Pt 2):S29-36. PMID: 12586082.
    Full Text (pdf)
  16. Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler, IJ. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004; 93(1): 78-86. PMID: 15047217.
    Full Text
  17. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in anti-vascular therapy in human ovarian carcinoma. Clin Cancer Res 2004; 10(3): 897-908. PMID: 14871965.
    Abstract
  18. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71. PMID: 16203789.
    Abstract
  19. Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res. 2005 Jul 1;11(13):4923-33. PMID: 16000591.
    Abstract
  20. Hu L, Hofmann J, Jaffe RB. Phosphatidylinostol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res. 2005 Nov 15;11(22):8208-12. PMID: 16299254.
    Abstract
  21. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res. 2006 Sep 1;66(17):8633-9. PMID: 16951177.
    Abstract
  22. Hu L, Ferrara N, Jaffe RB. Paracrine VEGF/VE-cadherin action on ovarian cancer permeability. Exp Biol Med (Maywood). 2006 Nov;231(10):1646-52. PMID: 17060686.
    Abstract
  23. Lin YG, Han LY, Kamat AA, Merritt WM, Landen CN, Deavers MT, Fletcher MS, Urbauer DL, Kinch MS, Sood AK. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007 Jan 15;109(2):332-40. PMID: 17154180.
    Abstract
  24. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan 1;67(1):281-8. PMID: 17210709.
    Abstract
  25. Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin YG, Han HD, Mangala L, Bankson J, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G.  An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.  J Clin Invest. 117(12):4044-4054, 2007. PMCID: PMC2104494.
    Abstract
  26. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15;67(4):1757-68. PMID: 17308118.
    Abstract
  27. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007 Apr 9;96(7):1083-91. Epub 2007 Mar 13. PMID: 17353927.
    Abstract
  28. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB, Sood AK. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res. 2007 Jun 1;13(11):3423-30. PMID: 17545551.
    Abstract
  29. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res. 2007 Jul 15;13(14):4209-17. PMID: 17634550.
    Abstract
  30. Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer. Dis Markers. 2007;23(5-6):419-31. PMID: 18057525.
    Abstract
  31. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov 15;67(22):10976-83. PMID: 18006843.
    Abstract
  32. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood AK. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst. 2008 Mar 5;100(5):359-72. Epub 2008 Feb 26. PMID: 18314475.
    Abstract
  33. Spannuth WA, Sood AK, Coleman RL; Medscape. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol. 2008 Apr;5(4):194-204. Epub 2008 Feb 12. PMID: 18268546.
    Full Text
  34. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. 2008 Nov;10(11):1259-67. PMCID: PMC2570602.
    Abstract
  35. Sanguino AM, Lopez-Berestein G, Sood AK. Strategies for in vivo siRNA delivery in cancer treatment. Mini Reviews in Medicinal Chemistry 8:248-255, 2008. PMID: 18336345.
    Abstract
  36. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Seminars in Cancer Biology 18:164-170, 2008. PMCID: PMC2424028.
    Full Text
  37. Sood AK, Birrer MJ. Highlights from the 2008 Annual Meeting of the American Association for Cancer Research. Gynecologic Oncology 110:5-6, 2008. PMID: 18595162.
    Full Text (pdf)
  38. Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, Degeest K, Langley RR, Lucci JA 3rd, Cole SW, Lubaroff DM, Sood AK. Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res. 2008 Nov 1;14(21):6839-46. PMCID: PMC2716059.
    Abstract
  39. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18;359(25):2641-50. PMCID: PMC2710981.
    Abstract
  40. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 1;124(5):1045-53. PMCID: PMC2668132.
    Abstract
  41. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun;8(11):1027-34. Epub 2009 Jun 24. PMID: 19395869.
    Abstract
  42. Mangala LS, Han HD, Lopez-Berestein G, Sood AK. Liposomal siRNA for Ovarian Cancer. Methods Mol Biol. 2009;555:29-42. PMID: 19495686.
    Full Text (pdf)
  43. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009 Jun;5(5):591-600. PMID: 19519199.
    Abstract
  44. Kamat AA, Coffey D, Merritt WM, Nugent E, Urbauer D, Bassett R, Landen CN, Han LY, Lin YG, Spannuth W, Agoulnik AI, Edwards C, Broaddus R, Gershenson DM, Coleman RL, Sood AK. EphA2 Overexpression is Associated with Lack of Hormone Receptor Expression and Poor Outcome in Endometrial Cancer. Cancer 115(12):2684-2692, 2009. PMID: 19396818.
    Abstract
  45. Kamat AA, Baldwin M, Urbauer D, Dang D, Nugent E, Han LY, Landen CN, Stone RL, Nick AM, Godwin A, Karlan B, Simpson JL, Gershenson DM, Schmandt R, Mueller P, Coleman RL, Bischoff FZ, Sood AK. Plasma cell-free DNA in ovarian cancer: An independent predictive biomarker of clinical outcome. Cancer, In Press.

© 2014 The University of Texas MD Anderson Cancer Center